MULTIPLE MYELOMA

During a live virtual event, Faith E. Davies, MD, discussed treatment options for a patient with multiple myeloma who relapsed after multiple lines of treatment including autologous stem cell transplant.

Treatment options have expanded widely for patients with multiple myeloma over the past several years, resulting in significantly improved outcomes for these patients.

During a Targeted Oncology case-based roundtable event, Sumit Madan, MD, discussed the case of a 55-year-old patient with multiple myeloma who was refractory to multiple lines of therapy.

Ajay Chari, MD, discusses new blood testing options for patients with multiple myeloma.

During a Targeted Oncology case-based roundtable event, Luciano J. Costa, MD, PhD, discussed various treatment regiments for a patient with newly diagnosed multiple myeloma.

Prerna Mewawalla, MD, looks back at a decade of advancements in the multiple myeloma space.

Jesus Berdeja, MD, discusses the safety profile observed with the newly approved chimeric antigen receptor T-cell therapy, ciltacabtagene autoleucel as observed in the phase 1/2 CARTITUDE-1 clincial trial.

Jesus Berdeja, MD, shares factors oncologists in the community should consider when referring patients for chimeric antigen receptorT-cell therapy with the newly approved agent ciltacabtagene autoleucel.

In an interview, Jesus Berdeja, MD, discussed the introduction of ciltacabtagene autoleucel into the treatment landscape for relapsed/refractory multiple myeloma, how it may differ from idecabtagene vicleucel, and the future of CAR T-cell use in the space.

The FDA has granted fast track designation to HPN217, for the treatment of patients with relapsed or refractory multiple myeloma, which is being evaluated in a phase 1/2 clinical trial.

Ciltacabtagene autoleucel had been granted FDA approval for the treatment of select patients with relapsed or refractory multiple myeloma.

During a Targeted Oncology case-based roundtable event, Kenneth Shain, MD, PhD, discussed the case of a patient whose multiple myeloma progressed 1 year after treatment with daratumumab, bortezomib, and dexamethasone.

There are still a lot of things that are ongoing, and the myeloma field is evolving with new treatments, according to Mark Bustoros, MBBCh.

During a live virtual event, Mohamed Baljevic, MD, discussed how to select and sequence combination regimens for multiple myeloma while considering eligibility for autologous stem cell transplant.

During a live virtual event, Natalie Callander, MD, discussed real-world experience with the efficacy of belantamab mafodotin and whether it can be chosen instead of chimeric antigen receptor T-cell therapy.

Jeffrey Zonder, MD, discusses the efficacy results of a first-in-human trial of a bispecific monoclonal antibody in patients with relapsed/refractory multiple myeloma.

During a live virtual event, Muhamed Baljevic, MD, discussed what factors determine whether a patient with stage II multiple myeloma could receive autologous stem cell transplant.

During a live virtual event, Natalie Callander, MD, discussed possible treatment options for a patient who relapsed several years after successful treatment of multiple myeloma with bortezomib, lenalidomide, and dexamethasone.

The anti-CD47 antibody, AO-176, has been granted an FDA orphan drug designation for relapsed or refractory myeloma treatment and is being assessed in a phase 1/2 study.

Jeffrey Zonder, MD, discusses the safety results of a first-in-human trial of a bispecific monoclonal antibody in patients with relapsed/refractory multiple myeloma.

During a live virtual event, Saad Zafar Usmani, MD, discussed the findings of the CASSIOPEIA and GRIFFIN studies of daratumumab and lenalidomide in patients with newly diagnosed multiple myeloma.

During a live virtual event, Saad Zafar Usmani, MD, discussed 2 studies of drug combinations in patients with multiple myeloma with or without stem cell transplants.

In an interview with Targeted Oncology, Shaji Kumar, MD, discussed the current standard of care in multiple myeloma, along with the need for risk stratification in this patient population.

Innovative approaches in multiple myeloma that focus on cellular therapies offer hope to patients with multiple myeloma.

Gurbakhash Kaur, MD, discusses the use of bispecific T-cell engagers as an alternative to chimeric antigen receptor (CAR) T-cell therapy for the treatment of multiple myeloma.